Edwards Lifesciences/$EW
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Ticker
$EW
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
15,800
ISIN
US28176E1082
Website
EW Metrics
BasicAdvanced
$46B
11.13
$7.02
1.13
-
Price and volume
Market cap
$46B
Beta
1.13
52-week high
$95.25
52-week low
$58.93
Average daily volume
4.2M
Financial strength
Current ratio
4.454
Quick ratio
3.334
Long term debt to equity
6.63
Total debt to equity
6.863
Interest coverage (TTM)
77.41%
Profitability
EBITDA (TTM)
1,688.2
Gross margin (TTM)
79.50%
Net profit margin (TTM)
75.71%
Operating margin (TTM)
27.75%
Effective tax rate (TTM)
10.93%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
8.42%
Return on equity (TTM)
16.51%
Valuation
Price to earnings (TTM)
11.134
Price to revenue (TTM)
8.413
Price to book
4.53
Price to tangible book (TTM)
6.39
Price to free cash flow (TTM)
74.561
Free cash flow yield (TTM)
1.34%
Free cash flow per share (TTM)
104.89%
Growth
Revenue change (TTM)
8.23%
Earnings per share change (TTM)
201.77%
3-year revenue growth (CAGR)
1.02%
10-year revenue growth (CAGR)
8.73%
3-year earnings per share growth (CAGR)
42.45%
10-year earnings per share growth (CAGR)
18.04%
What the Analysts think about EW
Analyst ratings (Buy, Hold, Sell) for Edwards Lifesciences stock.
Bulls say / Bears say
Edwards Lifesciences' Transcatheter Mitral and Tricuspid Therapies (TMTT) segment experienced a 58% sales increase in Q1 2025, driven by the adoption of PASCAL and EVOQUE systems, indicating strong growth potential in this market. (panabee.com)
The company raised its full-year 2025 TMTT sales guidance to $530-$550 million, reflecting confidence in sustained demand and market expansion. (panabee.com)
Edwards Lifesciences maintains a strong financial position with approximately $3.1 billion in cash and cash equivalents as of March 31, 2025, providing flexibility for strategic investments and operations. (ir.edwards.com)
Analysts have reduced their revenue and EPS estimates for Edwards Lifesciences, forecasting a 6.5% decline in sales and a 10% drop in EPS for 2024, indicating potential challenges ahead. (simplywall.st)
The company's Transcatheter Aortic Valve Replacement (TAVR) sales growth has decelerated to 6%, down from prior periods, suggesting potential market saturation or increased competition. (panabee.com)
Edwards Lifesciences faces unresolved tax disputes with the IRS amounting to over $269 million and with the Italian Tax Authority for over $110 million, posing material financial risks. (panabee.com)
Data summarised monthly by Lightyear AI. Last updated on 29 Jun 2025.
EW Financial Performance
Revenues and expenses
EW Earnings Performance
Company profitability
EW News
AllArticlesVideos
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
Business Wire·1 month ago
Trade Tracker: Bill Baruch buys Edwards Lifesciences
CNBC Television·1 month ago
Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Edwards Lifesciences stock?
Edwards Lifesciences (EW) has a market cap of $46B as of June 30, 2025.
What is the P/E ratio for Edwards Lifesciences stock?
The price to earnings (P/E) ratio for Edwards Lifesciences (EW) stock is 11.13 as of June 30, 2025.
Does Edwards Lifesciences stock pay dividends?
No, Edwards Lifesciences (EW) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Edwards Lifesciences dividend payment date?
Edwards Lifesciences (EW) stock does not pay dividends to its shareholders.
What is the beta indicator for Edwards Lifesciences?
Edwards Lifesciences (EW) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.